• Conference to focus on the latest in personalized medicine.
• New clinical data on diagnostic methods and therapeutics presented.
• Press conference to be held on Sept. 28 at 1:00 p.m. MT.
DENVER — The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development  from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.
Recent advances in genomics, proteomics, molecular imaging and other new technologies are leading to a molecularly based reclassification of cancer. These approaches allow for a more precise understanding of a patient’s tumor and a more personalized, targeted approach to therapy.
“This emerging understanding, together with the enhanced ability to characterize tumors from individual patients, creates many opportunities for improved treatment of malignancy and accelerated development of new therapeutics,” said Program Chairperson Gordon B. Mills, M.D., Ph.D., chair of the department of systems biology at the University of Texas MD Anderson Cancer Center.
Mills will host a press conference on some of the new diagnostic methods under development on Sept. 28, at 1:00 p.m. MT. Reporters who cannot attend the press conference in person can call in using the following information:
• U.S. and Canada: (888) 282-7404
• International: (706) 679-5207
• Access Code: 97080252
# # #
Follow the AACR on Facebook: http://www.facebook.com/aacr.org 
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists, providing a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
In Denver, Sept. 27-30: